Ganga Pharmaceuticals Limited

GANGAPHARM6

INE615T01017

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:55 2024-06-24 am EDT			5-day change	1st Jan Change
24.67 ^INR	-.--%		-.--%	-13.41%

May. 16	Ganga Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI
Jan. 19	Ganga Pharmaceuticals Limited announced that it has received INR 17.0625 million in funding from Lenus Finvest Pvt Ltd, Plutus Capital Management Llp	CI

Ganga Pharmaceuticals Limited announced that it has received INR 17.0625 million in funding from Lenus Finvest Pvt Ltd, Plutus Capital Management Llp

January 18, 2024

On January 19, 2024, Ganga Pharmaceuticals Limited closed the transaction. The company has now issued 775,000 Equity shares at issue price of INR 14 for gross proceeds of INR 10,850,000 and 1,775,000 convertible warrants at issue price of INR 3.5 per warrant for gross proceeds of 6,212,500; for total gross proceeds of INR 17,062,500. The transaction has been approved by the shareholders of the company.

Latest news about Ganga Pharmaceuticals Limited

Ganga Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2024	May. 16	CI
Ganga Pharmaceuticals Limited announced that it has received INR 17.0625 million in funding from Lenus Finvest Pvt Ltd, Plutus Capital Management Llp	Jan. 18	CI
Ganga Pharmaceuticals Limited announced that it expects to receive INR 21 million in funding from Lenus Finvest Pvt Ltd, Plutus Capital Management Llp	Dec. 03	CI
Ganga Pharmaceuticals Board to Consider Issuing Equity, Convertible Warrants to Raise Funds	Nov. 27	MT
Ganga Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended September 30, 2023	Nov. 08	CI
Ganga Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-08-22	CI
Ganga Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended September 30, 2022	22-11-11	CI
Ganga Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2022	22-05-25	CI
Ganga Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2021	21-06-28	CI
Ganga Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended September 30, 2020	20-11-05	CI
Ganga Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2020	20-06-27	CI
Ganga Pharmaceuticals Limited Announces Management Changes	20-05-25	CI
Ganga Pharmaceuticals Limited Announces the Appointment and Re-Designation of Sanjay Kulkarni as Executive Director	19-08-27	CI
Ganga Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2019	19-05-13	CI
874,550 equity shares of Ganga Pharmaceuticals Limited are subject to a Lock-Up Agreement Ending on 23-FEB-2019.	19-02-22	CI
Ganga Pharmaceuticals Limited Reports Unaudited Standalone Earnings Results for the Half Year Ended September 30, 2018	18-11-05	CI
Ganga Pharmaceuticals Limited Appoints Anagh B. Sharma as Chief Financial Officer	18-09-06	CI
Ganga Pharmaceuticals Limited Announces Resignation of Ganesh Jyothimani Paradeshi, Chief Financial Officer	18-08-30	CI
Ganga Pharmaceuticals Limited Announces Audited Standalone Earnings Results for the Half Year and Full Year Ended March 31, 2018	18-05-28	CI
Ganga Pharmaceuticals Limited Reports Unaudited Standalone Earnings Results for the Half Year Ended September 30, 2017	17-11-09	CI
Ganga Pharmaceuticals Limited Reports Audited Earnings Results for Fourth Quarter and Full Year Ended March 31, 2017	17-05-22	CI
2,106,950 equity of Ganga Pharmaceuticals Limited are subject to a Lock-Up Agreement Ending on 23-FEB-2017.	17-02-22	CI
Ganga Pharmaceuticals Limited Reports Unaudited Standalone Earnings Results for the Half Year Ended September 30, 2016	16-11-08	CI
Ganga Pharmaceuticals Limited Reports Audited Standalone Earnings Results for the Half Year and Full Year Ended March 31, 2016	16-05-26	CI
Ganga Pharmaceuticals Limited Appoints Priti Kothari Bhaiya as Company Secretary and Compliance Officer to Replace Mustafa Shabbir Badami	16-03-22	CI

Chart Ganga Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

Ganga Pharmaceuticals Limited is an India-based company, which is engaged in the production of ayurvedic medicines. The Company is also into marketing and distribution of ayurvedic medicines. It offers ayurvedic medicines in various categories, including acidity, antidandruff, antioxidants, blood purifier and skin disorder, constipation, cough and cold, dental care, diarrhea, ear care, female tonic, hair care, hemorrhoids and piles, indigestion, iron tonic, joint pains, kidney stone, liver disorder, rejuvenation tonic, sleep inducers, and herbal cosmetics. Its products include Asuka tablets, Dendroil, Ashwo tablets - tonic for body and mind, Raktaj tablets/syrup - for skin disorders, Nirmalaya (proprietary) - relieves constipation, Khadira tablets (80 mg.) (A.S.S) - relieves cough, Danta Doshahar Manjan - gum and teeth protective, Holetrica capsule - checks diarrhea and corrects digestion, Karnaraj drops (proprietary) - ear drops, Femoherb syrup/tablets, and Mahabhrungraj oil.

Sector

Pharmaceuticals

Calendar

2024-11-06 - Q2 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GANGA PHARMACEUTICALS LIMITED	-13.41%	1.43M
ELI LILLY AND COMPANY	+56.86%	823B
NOVO NORDISK A/S	+39.66%	641B
JOHNSON & JOHNSON	-6.57%	352B
MERCK & CO., INC.	+17.32%	324B
ABBVIE INC.	+9.94%	301B
ASTRAZENECA PLC	+15.30%	241B
ROCHE HOLDING AG	+1.47%	223B
NOVARTIS AG	+13.60%	218B
AMGEN INC.	+7.98%	167B